Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Hospira Will Acquire Indian API Facility
by Michael McCoy
September 3, 2012
| A version of this story appeared in
Volume 90, Issue 36
The injectable drug maker Hospira has agreed to acquire an active pharmaceutical ingredient manufacturing facility and related R&D operation from India’s Orchid Chemicals & Pharmaceuticals. Hospira says buying the FDA-inspected plant, for about $200 million, will reduce its costs and support continued supply of key antibiotics. The plant, in Aurangabad, employs some 640 chemists, engineers, and technicians. The R&D facility, in Chennai, employs 160 scientific personnel. Hospira acquired Orchid’s generic injectable drug business in 2010.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter